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Abstract: Hematopoiesis, the process of hematopoietic cell production, largely takes place in the bone marrow (BM) of 
humans. This process follows a stepwise manner in which hematopoietic stem cells give rise to progenitor cells and they 
develop the terminally differentiated cells along each lineage through a sequential series of stages. Consequently, 
constant changes would occur in the gene expressions leading to morphological or functional changes necessary for 
different stages of maturation. These changes provide us with guides to differentiate different subsets of hematopoietic 
hierarchy based on the cell surface antigen markers and will help us to isolate various cells from the hematopoietic 
hierarchy. Here we have a short review on the changes of these surface markers during different stages of development 
and we have applied an algorithmic approach for the isolation of all these cells based on our current understandings of 
this system. 
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INTRODUCTION 
In humans, the process of hematopoietic cell 
production (Hematopoiesis) occurs largely in the bone 
marrow (BM). Only the T-cell differentiation occurs 
outside the BM, principally within the thymus. This 
process begins with a quiescent stem cell which is 
stimulated with various environmental factors and gives 
rise to progenies differentiating along multiple lineages.  
The current model for describing the normal 
hematopoiesis considers a relatively linear fashion for 
differentiation along each lineage through a sequential 
series of stages. The final products are fully functional 
mature cells which are needed for the performance of 
routine tasks of the hematopoietic system. The 
maturation of hematopoietic cells along each lineage is 
tightly controlled by sequential expression of genes and 
their products [1]. Consequently, the pattern of genes 
expression and their resultant products shows constant 
and reproducible changes during morphological or 
functional stages of maturation.  
A group of these proteins are located on the cell 
surface. They may have diverse functions such as 
serving as growth factor receptors, adhesion 
molecules, extracellular enzymes, and signal transduc- 
tion molecules. Many of these cell surface proteins 
were simply identified by their antigenic reactivity and 
the functions for some of these molecules is not clearly 
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known. Some of these cell-surface antigens are 
restricted to a specific cell lineage, while others may be 
more widely expressed but their levels of expression 
varies with maturational stage or activation state. This 
may aid us in identification and isolation of different 
cells within diverse maturational stages based on their 
patterns of cell surface antigen expression [2].
 
HEMATOPOIETIC STEM AND PROGENITOR CELLS 
Both repair of the injured tissues and formation of 
new tissues are dependent on the quiescent stem cells 
localized within specific niches in each organ [3]. Acti- 
vation of stem cells is closely controlled by environ- 
mental stimulations by the surrounding microenviron- 
ment and follows a sequence of events at the genetic 
and epigenetic levels [4]. This tight controlling machine 
leads to establishment of a hierarchy starting from the 
slow-cycling stem cell with subsequent transiently 
amplifying precursors with a high proliferative capacity, 
but with lineage-commitment properties. At the end of 
this spectrum are the non-cycling, terminally differentia- 
ted cells that carry on the organ functions [5].  
During the development of terminally differentiated 
cells, the stem cells themselves remain undifferen- 
tiated, which passes through their unique capacity for 
self-renewal. When a stem cell divides into two fates, 
only one of the resulting daughter cells enters the path 
for increasing specificity and the other one instead 
remains undifferentiated [6]. This phenomenon keeps 
the numbers in the overall stem cell pool constant, 
whereas the proliferation of the descendant progenitors 
can rapidly provide populations of specific cell types in 
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response to changing needs. The capacity of stem 
cells to recreate themselves is called self-renewality 
and is one of the most important defining properties of 
stem cells. This gives them a potential for a nearly 
unlimited life span. Progenitor cells do have some 
ability to renew themselves as well, but their ability to 
reproduce themselves is restricted by an internal 
counting mechanism and only finite rounds of 
duplication can be preceded. The ability of the 
progenitors' offspring to multiply declines steadily as 
differentiation goes on (Figure 1). Hematopoietic stem 
cells (HSCs) are defined as single cells with lifelong 
ability to self-renew as well as differentiate to produce 
all blood cell lineages (multipotency). 
 
Figure 1: When a stem cell divides into two fates, only one of 
the resulting daughter cells enters the path for increasing 
specificity and the other one instead remains undifferentiated. 
This process is called self-renewality.Consequently the 
numbers of stem cells remains constant, whereas the 
descndant progenitors will provide the terminally 
differentiated cells needed for proper tissue functioning. 
Progenitor cells do have some abilities to renew themselves 
as well, which is limited by an internal counting mechanism 
leading to only finite rounds of duplication. 
These hematopoietic cells with repopulating acti- 
vities have been identified within CD34
+
 cells [7]. Civin 
and colleagues in 1981 reported the presence of a 
marker, at first named as My10, on about 1% to 4% of 
BM cells which was also present on KG1A leukemia 
cells and later shown to be CD34 [8]. In 1988, 
Bernstein and colleagues showed that transplantation 
of CD34
+
 cells can reconstitute hematopoiesis in letha- 
lly irradiated baboons [9], and the Thomas group in 
1990 performed the first human CD34
+
 enriched 
autologous graft with successful engraftment in a 
patient with a brain neoplasm [10]. Primitive hema- 
topoietic cells that tend to lose their self-renewal 
potential start to express higher levels of the CD38 
antigen while becoming more committed to differen- 
tiate. Therefore, HSC are found within the CD34
+
CD38

 
cell fraction [11-13]. In human, two groups of cells can 
fulfill the definition for HSCs and therefore both can be 
named as stem cell. But only one can maintain a long-
term multilineage reconstitution (LTMR) in allogenic 
transplants and therefore has been named as long 
term HSC (LT-HSC). In irradiation-reconstitution experi- 
ments, human CD34
+
CD90
+
Lin

 cells were the only 
cells in human adult and fetal marrow, cord blood, fetal 
liver, and mobilized peripheral blood (MPB) that 
achieved LTMR [14]. So, LT-HSCs are 
CD34
+
CD38

CD90
+
Lin

 cells. These cells can give rise 
to a progeny, with the phenotype of 
CD34
+
CD38

CD90

Lin

, which has a short-term self-
renewality potential for 10 weeks despite the ability to 
produce all blood lineages. They are called short term 
HSCs (ST-HSC) [14]. In contrast, in the murine system, 
LT-HSCs are CD34

CD38
+
 cells and the more 
committed progenitors are showing a CD34
+
CD38

 
phenotype [15, 16]. Therefore, CD38 is a primitive 
marker in mice and a differentiation marker in humans. 
In addition to the mentioned markers, other antigen 
combinations have been used to discriminate more 
primitive from more mature CD34
+
 cells. Some of the 
combinations used are CD34
+
c-kit
+
CD38

CD33

Rho- 
123

 [17], CD34
+
HLA-DR

Lin

 [18], or CD34
+
CD38

Rho- 
123
low 
Lin

 [19], and CD133
+
ALDH
hi
Lin

 [20]. 
 
The CD133 marker, also known as prominin-1 or 
AC133 antigen, is also co-expressed on most of the 
CD34
+
 cells, and can characterize stem cells in 
humans [21-23]. Investigations have shown the 
presence of very rare undifferentiated cells with stem 
cell properties within the Lin

CD34

CD38

 cell fraction 
which expresses CD133 [24-26]. It seems that CD133 
describes the most primitive human hematopoietic cells 
more precisely than CD34 [7].  
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Human hematopoietic progenitors have also been 
characterized. Manz et al. described the characteristics 
of the "Common Myeloid Progenitor Cell (CMP)", 
"Granulocyte Monocyte Progenitor Cell (GMP)", and 
"Megakaryocyte Erythrocyte Progenitor Cell (MEP)" 
within the CD34
+
CD38
+
 fraction of hematopoietic cells 
from both the adult bone marrow and cord blood by the 
differential expression of CD45RA and IL3Ra (CD123) 
Table 1:  Expression of Surface Antigens during Different Stages of Granulopoiesis (Neutrophilic Maturation) 
 GMP Myeloblast Promyelocyte Myelocyte Metamyelocyte Band Cell Neutrophil 
CD10       ++ 
CD11a ++ +/++ +/++ +/++ +/++ +/++ +/++ 
CD11b    +/++ ++ ++ ++ 
CD11c    ++ ++ ++ ++ 
CD13 ++ ++/+++ ++/+++ + +/++ ++ +++ 
CD14 NA
 b
      + 
CD15  + +++ +++ +++ +++ +++ 
CD15s ++ +++ +++ ++ + + +++ 
CD16     + ++ +++ 
CD18 ++ ++ + +++ ++   
CD24    ++ ++ ++ ++ 
CD29 +++ ++ ++ ++ + + + 
CD31 +++ ++ ++ ++ + + + 
CD32 ++ ++ ++ ++ ++ ++ +++ 
CD33 +++ +++ +++ ++ + + + 
CD34 + ++      
CD35      ++ ++ 
CD44 +++ +++ ++ + + ++ +++ 
CD45 NA
 a
 +/++ +/++ ++ ++ ++ ++ 
CD45RA ++ + +     
CD45RO    + + ++ +++ 
CD49d +++ ++ ++ ++ +   
CD49e +++ ++ ++ ++ + + + 
CD54 ++ ++ ++ +/ +/ +/ +/ 
CD55 +++ +++ + + +++ +++ +++ 
CD59 +++ +++ +++ +++ +++ +++ +++ 
CD62L ++ ++ ++ ++ ++ ++ ++ 
CD64 ++ + + ++ ++   
CD65 + + ++ ++ ++ +++ +++ 
CD66a    ++ ++ ++ ++ 
CD66b   +++ +++ ++ ++ ++ 
CD82 +++ ++ ++ ++ ++ ++ ++ 
CD87      ++ ++ 
CD117 NA 
a
 ++ +     
CD162 +++ +++ +++ +++ +++ +++ +++ 
[Modified from Elghetany MT: Surface Antigen Changes during Normal Neutrophilic Development: A Critical Review. Blood Cells Mol Dis 2002; 28: 260-74]. 
GMP means granulocyte monocyte progenitor cell; +++ means strong expression; ++ means moderate expression; + means weak expression; +/ means very weak 
expression;  means no expression; NA means Data Not Available; a means possible expression; b means possible not expressing. 
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[27]. They showed that CMP (CD123
+
CD45RA

) can 
give rise to both the GMP (CD123

CD45RA

) and the 
MEP (CD123
low
CD45RA
+
). None of these cells 
contained a lymphoid developmental potential [14]. 
Instead, in 1995, Galy et al. described CD34
+
CD- 
38
+
Lin

CD10
+
CD45RA
+
 cells within human BM that 
could give rise to T, B, natural killer (NK), and dendritic 
cells and are common lymphoid progenitor cells [28].  
GRANULOPOIESIS 
The process of Granulocyte maturation 
(Granulopoiesis) starts from myeloblasts through a 
linear process into morphological stages historically 
termed promyelocytes, myelocytes, metamyelocytes, 
bands, and neutrophils. Only the last fates within this 
lineage (band/neutrophils) are fully functional and have 
bactericidal potentials. The antigenic changes during 
these stages have been widely studied from an 
immunophenotypic perspective. [2]. 
Among the CD markers, CD15 needs special 
attention in granulocyte maturation charts. Early 
studies suggested the expression of CD15 from GMP 
through the segmentation phase of neutrophils [29]. In 
other studies, expression of CD15 was shown at the 
blast stage but not on CD34
+
 cells [30-32]. More recent 
studies indicate that a small portion of CD34
+
 bone 
marrow precursor cells do expresses CD15 and this 
expression increases significantly with sequential 
maturation from promyelocytes to neutrophils [33, 34]. 
So it seems that expression of CD15 is the only key to 
differentiate between myeloblast and GMP [35]. A 
summary of antigen expression during different deve- 
lopmental stages of neutrophils is shown in Table 1. 
MONOCYTE MATURATION 
Monocytes maturation starts from monoblasts as a 
continuum through one intermediate stage termed the 
promonocyte [32, 36]. With maturation of monoblasts 
from GMPs, expression of CD4 begins and increases 
with more differentiation. In contrast, CD34 expression 
stops with transition from monoblasts toward promono- 
cytes. The expression of CD64, HLA-DR, and CD33 
are retained at relatively high levels on maturing 
monocytes unlike the myeloid counterparts and may 
serve as useful monocytic markers [2]. 
In general, the presence of CD4 on monoblast and 
its progenies can help differentiate them from 
myelocytic lineages and also GMP. The presence of 
CD33 makes them different from T-cell subtypes [2]. A 
summary of antigen expression during different deve- 
lopmental stages of Monocytes is shown in Table 2. 
Table 2:  Expression of Surface Antigens during Diffe- 
rent Stages of Monocytic Maturation 
 GMP Monoblast Promonocyte Monocyte 
CD4  /+ + + 
CD11b   ++ +++ 
CD13 ++ ++ +/++ ++/+++ 
CD14 NA
 b  +/++ +++ 
CD15   ++ + 
CD16    /+ 
CD33 +++ +++ +++ +++ 
CD34 +/++ +   
CD36   ++ +++ 
CD45 NA
 a
 + ++ +++ 
CD64 ++  ++ +++ 
HLA-DR ++ ++ +++ ++/+++ 
[Modified from Wood B: Multicolor immunophenotyping: human immune 
system hematopoiesis. Methods Cell Biol. 2004; 75: 559-76.] 
GMP means granulocyte monocyte progenitor cell; +++ means strong 
expression; ++ means moderate expression; + means weak expression; +/ 
means very weak expression;  means no expression; NA means Unknown 
Data Not Available; a means possible expression; b means possible not 
expressing. 
ERYTHROPOIESIS 
Erythropoiesis is the process of formation of red 
blood cells. The maturational stages of this process 
have historically been divided into proerythroblasts, 
basophilic erythroblasts, polychromatophilic erythro- 
blasts, and erythrocytes based on their morphological 
appearance. The morphological changes have shown 
reasonable correlations with the observed immune- 
phenotypes [37-40]. The expression of CD34 is high on 
MEPs but low on proerythroblasts. The expression of 
CD38 also decreases with maturations. Proerythro- 
blasts show high levels of CD71 and CD235a, both of 
which being absent on MEPs. It should be noted that 
the preparations of BM samples for evaluating matura- 
tional stages during erythropoiesis differ from those for 
other lineages. For example, usage of lysing reagents 
such as NH4Cl generally leaves only proerythroblasts 
for evaluation [2]. A summary of antigen expression 
during different developmental stages of erythrocytes is 
shown in Table 3. 
MEGAKARYOPOIESIS 
Megakaryopoiesis is the process that leads to the 
production of the platelets. The development of the 
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platelet passes through megakaryoblast, promegaka- 
ryocytes, and megakaryocytes. Production of the 
platelets from mature megakaryocytes needs cytoplas- 
mic fragmentation occurring through a dynamic and 
regulated process, called proplatelet formation. This 
process consists of pseudopodial elongations with final 
breaking into the blood. 
The hallmarks of this lineage are CD41 and CD61. 
CD41 is present on about 3% of marrow CD34
+
. These 
CD34
+
CD41
+
 cells are enriched in megakaryoblasts. 
The expression of CD41 precedes the detection of 
CD42 [41]. Thus, CD34
+
CD41
+
CD42

 cells correspond 
to true megakaryoblast whereas CD41
+
CD42
+
 cells 
give rise to promegakaryocytes and the expression of 
CD42 accompanies late differentiation steps. CD61 
expression starts with passing through MEP to megaka- 
Table 4: Expression of Surface Antigens during 
Different Stages of Megakaryopoiesis (Platelet 
Maturation) 
 MEP 
Megakaryo-
blast 
Promega-
karyocyte 
Mega-
karyocyte 
CD34 ++ /+   
CD38 ++ /+ + ++ 
CD41 ++ + + ++ 
CD42   /+ + 
CD61  + + ++ 
MEP means megakaryocyte–erythrocyte progenitor cell; +++ means strong 
expression; ++ means moderate expression; + means weak expression; +/ 
means very weak expression;  means no expression. 
ryoblast and can help differentiate these two cells. As 
the maturation of cells increases, the CD34 antigen 
disappears [42]. 
A summary of antigen expression during different 
developmental stages of megakaryocytes is shown in 
Table 4. 
CONCLUSION 
Although, to the best of our knowledge, no study 
has evaluated all the CD markers together simultane- 
ously, the sum of previous investigations can logically 
be mixed to reach the final picture of the whole 
hematopoietic hierarchy (Figure 2). 
Our current knowledge from the widely popular 
model of describing the hematopoietic hierarchy, the 
“sequential determination model”, provides us with 
guides to isolate different cells within different stages of 
maturation (Figure 3) and helps us differentiate various 
subsets of hematopoietic hierarchy based on cell 
surface antigen markers. However, there are still some 
missing parts; for instance, the status of CD38 
expression on the Myeloblasts and Monoblasts is not 
determined. 
Unlike the classical sequential determination model, 
two human cord blood derived cell populations 
(CD34
+
CD45RA
high
CD10
+
Lin
 
and CD34
+
CD45RA
high- 
CD7
+
Lin
) 
have been described by Haddad and 
colleagues to contain robust myelomonocytic 
differentiation potentials despite being primed to 
Table 3: Expression of Surface Antigens during Different Stages of Erythropoiesis (Erythrocyte Maturation) 
 MEP Proerythroblast Basophilic Erythroblast Polychromatophilic Erythroblast Erythrocyte 
CD34 ++ /+    
CD36  ++ +++ ++  
CD38 ++ + /+   
CD45 ++ + /+   
CD45RA  NA NA NA NA 
CD71  +++ +++ +++  
CD117 ++ ++    
CD123  NA NA NA NA 
CD235a  +/++ +++ +++ +++ 
HLA-DR ++ ++ +   
Hemoglobin   /+ + +++ 
[Modified from Wood B: Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol. 2004; 75: 559-76.] 
MEP means megakaryocyte–erythrocyte progenitor cell; +++ means strong expression; ++ means moderate expression; + means weak expression; +/ means very 
weak expression;  means no expression; NA means Data Not Available. 
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develop the T-cell and NK cell or the B-cell lineage, 
respectively [43]. However, this CD34
+
CD38

CD7
+
 
population does not exist in the adult bone marrow [14]. 
Similarly, CD34
+
CD10

CD19

 cells are known to be 
committed to early B-cell development do still have the 
capacity to differentiate into NK-cells, T-cells and 
macrophages [44]. Additionally, CXCR4

CD34
+
CD19
+
 
B-cell progenitor cells have been shown to have 
potentials for granulocyte, macrophage, and red blood 
cell development [45]. 
 
Figure 2: A schematic representation for how different cells within hematopoietic hierarchy express various cell surface markers. 
26    Global Journal of Hematology and Blood Transfusion, 2014, Vol. 1, No.1  Armin Attar. 
The identification of progenitors with diverse cell 
fates has prompted new models of hematopoiesis [46-
50]; however, most of these models lack the consensus 
for a lineage branching map. A revised model to depict 
the developmental relationships between 
hematopoietic cell lineages has been proposed by 
Ceredig and collegues. This model involves grouping 
the pairwise relationships between lineage fates 
around a broken circle, and considers the 
hematopoietic hierarchy as continuum other than a 
branched stepwise model [51]. 
Although these new models may be more realistic, 
because the differentiation of hematopoietic cells is a 
continuous rather than a step-wise process, they 
models cannot help us in isolating cells from this 
spectrum and the classical models seem to be more 
practical for this purpose. 
 
Figure 3: A proposed algorithmic chart for isolation of cells within hematopoietic hierarchy based on the cell surface antigen 
markers. (Abbreviations: CLP=Common Lymphoid Progenitor cell, CMP = Common Myeloid Progenitor Cell, GMP = 
Granulocyte Monocyte Progenitor Cell, LT-HSC = Long Term Hematopoietic Stem Cell, MEP = Megakaryocytic Erythroid 
Progenitor Cell, MN = Mononuclear Cell, ST-HSC = Short Term Hematopoietic Stem Cell.). 
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